Format

Send to

Choose Destination
Food Chem Toxicol. 2009 Oct;47(10):2450-3. doi: 10.1016/j.fct.2009.07.001. Epub 2009 Jul 5.

Safety assessment of Lactobacillus brevis KB290 as a probiotic strain.

Author information

1
Research Institute, Kagome Co, Ltd, Tochigi, Japan. Takafumi_Yakabe@kagome.co.jp

Abstract

Lactobacillus brevis KB290 (KB290), a plant-derived probiotic lactic acid bacterium, reportedly improves gut health and stimulates immune function. Here we extensively investigated the geno-, acute, subacute, and subchronic toxicity of KB290 and its bacterial translocation potential. KB290 was non-mutagenic in the bacterial reverse mutation assay by the preincubation method. In the single oral dose toxicity test, KB290 at 10(9) cfu/ml was nontoxic at maximum capacity (20 ml/kg). When 10(8), 10(9), or 10(10) cfu/kg was administered daily to rats by gavage for 2 weeks (subacute assay), we observed no clear treatment-related effect and no evidence of bacterial translocation from the gastrointestinal tract. When it was administered for 13 weeks (subchronic assay), we again observed no clear treatment-related effect and no significant toxicological effect. Based on those results, we consider 10(10) cfu/kg per day, the highest dose tested, to be the no observed adverse effect level (NOAEL). These results suggest that KB290 is safe for human consumption.

PMID:
19583990
DOI:
10.1016/j.fct.2009.07.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center